Michał Andrzej Skrzypczyk

Dr. Michał Andrzej Skrzypczyk

Urology, Centre of Postgraduate Medical Education, Warsaw, Mazowieckie, Poland
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KBKonrad Bilski
Konrad Bilski
JDJakub Dobruch
Jakub Dobruch
MKMieszko Kozikowski
Mieszko Kozikowski
MSMichal Skrzypczyk
Michal Skrzypczyk
MOMaciej Oszczudłowski
Maciej Oszczudłowski
JOJerzy Ostrowski
Jerzy Ostrowski
Bladder cancer (BC) remains the most common malignancy of urinary tract. Sex-related differences in BC epidemiology, diagnosis, therapy, and outcomes have been reported. Throughout the recent years, extensive research has been devoted to genetic and molecular alterations in BC. Apart from the molecular background, another related concept which has been speculated to contribute to gender diversities in BC is the role of urinary pathogens in bladder carcinogenesis. Microbiome studies, fueled by the availability of high-throughput DNA-based techniques, have shown that perturbation in the microbiome is associated with various human diseases. The aim of this review is to comprehensively analyze the current literature according to sex-related differences in the microbiome composition in BC.

1 January 2018 in Central European Journal of Urology
Verified
Journal Article
Open access
YMYulian Mytsyk
Yulian Mytsyk
VDVictor Dosenko
Victor Dosenko
MSMichal Skrzypczyk
Michal Skrzypczyk
YBYuriy Borys
Yuriy Borys
YDYuriy Diychuk
Yuriy Diychuk
LMLubov Manyuk
Lubov Manyuk
The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...

24 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ŁBŁukasz Białek
Łukasz Białek
MRMarta Rydzińska
Marta Rydzińska
MVMalte W. Vetterlein
Malte W. Vetterlein
JDJakub Dobruch
Jakub Dobruch
MSMichal Skrzypczyk
Michal Skrzypczyk
In the era of antibiotic overuse and increasing antibiotic resistance, there is a gap in evidence regarding antibiotic stewardship, and in particular, perioperative antibiotic prophylaxis after urethral reconstruction. The aim of this systematic review was to evaluate the effectiveness and relevance of postoperative antibiotic prophylaxis after male pediatric and adult urethral reconstruction. An online search of MEDLINE database via PubMed was performed. The systematic review was registered in PROSPERO (CRD42022348555) and was conducted according to the PRISMA guidelines and AMSTAR 2 checklist. A narrative synthesis of included studies was performed. After the screening of 1176 publications, six studies regarding antibiotic prophylaxis after hypospadias reconstruction and two studies regarding antibiotic prophylaxis after urethroplasty in adults were eligible to be included in the systematic review. All but one of the studies on hypospadias repair showed no benefit from postoperative antibiotic prophylaxis. The level of evidence on postoperative antibiotic prophylaxis after urethroplasty in adults is low. Neither of the two studies included in the review showed a benefit from antibiotic use. Postoperative prophylaxis after hypospadias repair is not effective in preventing urinary tract infections and wound infections. It seems that the use of postoperative prophylaxis after urethroplasty in adults is also not beneficial, but there is a high need for high-quality scientific data.

12 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KBKonrad Bilski
Konrad Bilski
MKMieszko Kozikowski
Mieszko Kozikowski
MSMichal Skrzypczyk
Michal Skrzypczyk
ADAleksandra Dobruch
Aleksandra Dobruch
KHKees Hendricksen
Kees Hendricksen
JDJakub Dobruch
Jakub Dobruch
Sex-specific differences in outcomes of patients diagnosed with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have been reported with controversial findings. This study aims to investigate sex-specific diversities in the treatment and oncologic outcomes of primary HR-NMIBC in a multicenter setting. A multicenter retrospective analysis of 519 patients (388 men and 131 women) treated with transurethral resection (TUR) for primary HR-NMIBC was performed. Univariable and multivariable Cox regression models were used to investigate the association of clinico-pathologic features and generate hazard ratios (HRs). Second-look TUR (reTUR) was performed in 406 (78%) patients. A total of 218 (42%) of patients were subjected to an induction course of intravesical BCG (Bacillus Calmette–Guérin) plus maintenance therapy. The median follow-up was 44 months. Among the entire cohort, 238 (46%) and 86 patients (17%) had recurred and progressed to muscle-invasive disease (MIBC), respectively. Female sex was associated with increased risk of disease recurrence in the entire cohort: HR = 1.94, 95% CI = 1.48–2.55, p < 0.001 and HR = 1.91, 95% CI = 1.39–2.60, p < 0.001 in univariate and multivariate analysis, respectively. In patients subjected to reTUR and treated additionally with BCG, female sex was associated with increased risk of disease recurrence in univariate analysis (HR 1.81, 95% CI 1.07–3.06, p = 0.03), but not in multivariate analysis (HR 1.99, 95% CI 0.98–4.02, p = 0.06). There was no difference between sexes with regard to disease progression. HR-NMIBC diagnosed in females is associated with higher risk of disease recurrence when compared to males.

1 January 2014 in Central European Journal of Urology
Verified
Journal Article
Open access
MSMichal Skrzypczyk
Michal Skrzypczyk
JDJakub Tomasz Dobruch
Jakub Tomasz Dobruch
ŁNŁukasz Nyk
Łukasz Nyk
PSPrzemysław Szostek
Przemysław Szostek
SSStanisław Szempliński
Stanisław Szempliński
ABAndrzej Borówka
Andrzej Borówka
In some patients submitted to transurethral resection of the prostatic (TURP) or prostatectomy (OAE) due to benign prostate hyperplasia (BPH), pathological evaluations (PE) revealed coexistence of prostate cancer (PCa) and BPH. The aim of the study is to evaluate the incidence of PCa diagnosed incidentally in prostate specimens taken during BPH surgery, to assess the need of routine PE and to define the group of patients in whom PE could be abandoned without the risk of omitting clinically significant PCa. 968 consecutive men were subjected to surgical treatment due to BPH in Jan. 2004-Sep. 2010. 823 (85%) underwent TURP and 145 (15%) OAE. Incidental (Inc) PCa was diagnosed in 34(3.5%) pts. T1a and T1b stages were determined in 19 (2%) and 15 (1.5%) cases. Preoperative prostate biopsy due to abnormal prostate specific antigen (PSA) or digital rectal exam (DRE) was performed in 85 (8.8%) pts. Of PCa pts, 7 (20.58%) had undergone a cancer negative biopsy preoperatively. In BPH pts, 78 (8.35%) had undergone a prostate biopsy previously (p 6 only in 4 cases. Despite the fact of low PCa detection rate observed in our study, this condition was clinically relevant in 15 (1.5%) subjects. It is difficult to establish any cut off values of pts' age, Pv, serum PSA level suggestive of negligible risk for prostate cancer.

29 December 2015 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
MSMichal Skrzypczyk
Michal Skrzypczyk
ŁNŁ. Nyk
Ł. Nyk
PSP. Szostek
P. Szostek
SSS. Szempliński
S. Szempliński
ABA. Borówka
A. Borówka
JDJ. Dobruch
J. Dobruch
Despite complete resection, non-muscle invasive bladder cancers tend to recur. Therefore, their risk stratification was implemented to select adjuvant therapy. Immediate intravesical chemotherapeutic instillations were shown to decrease the risk of recurrence in those with low-risk disease. The purpose of the study was to determine the role of endoscopic assessment in the management of patients subjected to transurethral resection of the bladder tumour (TURBT). In 262 patients submitted to TURBT due to primary bladder tumour, the size and the number of the lesion(s) were noted and the stage as well as the grade of the tumour(s) were typed. The individual features were then scored according to the European Organisation of Research and Treatment of Cancer 'Bladder Calculator' and the lesions were classified into the low, intermediate and high risk of recurrence group. Clinical evaluation was then compared with pathological report and final triage. Based on the clinical data, 95 (36.25%), 105 (40.07%) and 3 (1.14%) patients were endoscopically assigned to the groups of low, intermediate and high risk of recurrence respectively. After pathological report, correct risk stratification was confirmed in 86 (90.5%), 95 (90.5%) and 3 (100%) patients respectively. Endoscopic assessment of bladder cancers allows to accurately establish the risk of recurrence and may facilitate implementation of adjuvant therapy before histological evaluation.